Most technical analysis of SINOPHARM GROUP help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for SINOPHARM from various momentum indicators to cycle indicators. When you analyze SINOPHARM charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd. Sinopharm is traded on OTC Exchange in the United States. A high-level view of SINOPHARM GROUP emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/E of 6.27, P/B of 0.9, profit margin of 1.45%. SINOPHARM GROUP has a market cap of 8.61 B, P/E of 6.27, ROE of 13.19%.
Methodology
Unless otherwise specified, financial data for SINOPHARM GROUP LTD is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. SINOPHARM (USA Stocks:SHTDY) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
SINOPHARM GROUP LTD may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking SINOPHARM GROUP inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
SINOPHARM GROUP financial ratios help frame valuation context across profits, cash flow, and enterprise value. They help compare SINOPHARM across valuation measures.
Raphi Shpitalnik ยท Junior Member of Macroaxis Editorial Board